These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33461835)

  • 1. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Whitaker JA; Parikh SA; Shanafelt TD; Kay NE; Kennedy RB; Grill DE; Goergen KM; Call TG; Kendarian SS; Ding W; Poland GA
    Vaccine; 2021 Feb; 39(7):1122-1130. PubMed ID: 33461835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
    Williams KV; Moehling Geffel K; Alcorn JF; Patricia Nowalk M; Levine MZ; Kim SS; Flannery B; Susick M; Zimmerman RK
    Vaccine; 2023 Jan; 41(3):862-869. PubMed ID: 36543682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Muchtar E; Koehler AB; Johnson MJ; Rabe KG; Ding W; Call TG; Leis JF; Kenderian SS; Hayman SR; Wang Y; Hampel PJ; Holets MA; Darby HC; Slager SL; Kay NE; Miao C; Canniff J; Whitaker JA; Levin MJ; Schmid DS; Kennedy RB; Weinberg A; Parikh SA
    Am J Hematol; 2022 Jan; 97(1):90-98. PubMed ID: 34699616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
    Niang M; Deming ME; Goudiaby D; Diop OM; Dia N; Diallo A; Ortiz JR; Diop D; Lewis KDC; Lafond KE; Widdowson MA; Victor JC; Neuzil KM
    Vaccine; 2020 Nov; 38(47):7526-7532. PubMed ID: 33012603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does prior vaccination affect the immune response to seasonal influenza vaccination among older adults? Findings from a prospective cohort study in a Northeastern Province of Thailand.
    Praphasiri P; Prasert K; Shrestha M; Ditsungnoen D; Chittaganpich M; Chawalchitiporn S; Dawood FS; Sirilak S; Mott JA
    PLoS One; 2023; 18(2):e0279962. PubMed ID: 36735691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
    Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
    Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
    Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
    Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
    Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
    Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
    Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.
    Héquet D; Pascual M; Lartey S; Pathirana RD; Bredholt G; Hoschler K; Hullin R; Meylan P; Cox RJ; Manuel O
    Vaccine; 2016 Jun; 34(31):3576-83. PubMed ID: 27219339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
    Lin SY; Wu ET; Lin CH; Shyu MK; Lee CN
    PLoS One; 2013; 8(6):e62983. PubMed ID: 23762229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.